Skip to main content
. 2013 May 5;73(6):1144–1150. doi: 10.1136/annrheumdis-2012-203028

Figure 1.

Figure 1

(A) Reduced flow-mediated dilatation (FMD) and (B) elevated CD31+/annexin V+/CD42b− endothelial microparticles (EMPs) in patients with systemic lupus erythematosus (SLE) versus controls.